GELESIS HOLDINGS INC (GLS) Stock Price, Forecast & Analysis
USA • New York Stock Exchange • NYSE:GLS • US36850R2040
GLS Key Statistics, Chart & Performance
The current stock price of GLS is 0.1586 USD. In the past month the price decreased by -33.92%. In the past year, price decreased by -96.82%.
GLS Technical Analysis
GLS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLS. Both the profitability and financial health of GLS have multiple concerns.
GLS Financial Highlights
Over the last trailing twelve months GLS reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS increased by 66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GLS Forecast & Estimates
8 analysts have analysed GLS and the average price target is 0.46 USD. This implies a price increase of 189.41% is expected in the next year compared to the current price of 0.1586.
For the next year, analysts expect an EPS growth of 78.59% and a revenue growth 80.41% for GLS
GLS Ownership
GLS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.08 | 383.716B | ||
| AMGN | AMGEN INC | 16.32 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.72 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.54 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.25 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.25 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GLS
Company Profile
Gelesis Holdings, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2020-07-07. The firm focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. The company is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.
Company Info
GELESIS HOLDINGS INC
501 Boylston Street, Suite 6102
Boston MASSACHUSETTS US
Employees: 93
Phone: 18573277737.0
GELESIS HOLDINGS INC / GLS FAQ
What does GELESIS HOLDINGS INC do?
Gelesis Holdings, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2020-07-07. The firm focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. The company is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.
Can you provide the latest stock price for GELESIS HOLDINGS INC?
The current stock price of GLS is 0.1586 USD. The price increased by 0.38% in the last trading session.
What is the dividend status of GELESIS HOLDINGS INC?
GLS does not pay a dividend.
How is the ChartMill rating for GELESIS HOLDINGS INC?
GLS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is GELESIS HOLDINGS INC (GLS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GLS.
How many employees does GELESIS HOLDINGS INC have?
GELESIS HOLDINGS INC (GLS) currently has 93 employees.
Can you provide the market cap for GELESIS HOLDINGS INC?
GELESIS HOLDINGS INC (GLS) has a market capitalization of 11.63M USD. This makes GLS a Nano Cap stock.